| Somerset Rehabilitation & Living Center | |
| 43 Owens St, Bingham, Maine 04920 | |
| (207) 672-4041 | |
| Name | Somerset Rehabilitation & Living Center |
|---|---|
| Location | 43 Owens St, Bingham, Maine |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 21 |
| Occupancy Rate | 90.48% |
| Medicare ID (CCN) | 205165 |
| Legal Business Name | North Country Associates, Inc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1447310644 |
| Organization Name | NORTH COUNTRY ASSOCIATES, INC |
| Doing Business As | SOMERSET LIVING CENTER |
| Address | 43 Owens St, Bingham, ME 04920 |
| Phone Number | 207-672-4041 |
News Archive
The Federal Government has announced a $560 million for new or upgraded cancer centres across Australia this week. The Cancer Council of Australia while welcoming this gesture has said that this is not the complete solution when it comes to helping regional and rural patients of Australia. This statement was made by the CEO Ian Olver who said that this "unprecedented" amount of money can go a long way to help but more support is needed. One of the regional cancer support networks has gone further to criticize the fact that so much is doled out in patient accommodation instead of advanced cancer treatment and care services.
A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.
ACT Biotech, a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly-potent nature of the antiangiogenic agent.
454 Life Sciences, a Roche Company, and NuGEN Technologies, announced today the development of a unique sample preparation method and high-throughput sequencing solution for small and degraded RNA samples.
Smart Use Solutions, the leading provider of inventory management software to the healthcare sector today announced it has been awarded Primary Supplier status for the provision of NHS inventory management solutions.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The Federal Government has announced a $560 million for new or upgraded cancer centres across Australia this week. The Cancer Council of Australia while welcoming this gesture has said that this is not the complete solution when it comes to helping regional and rural patients of Australia. This statement was made by the CEO Ian Olver who said that this "unprecedented" amount of money can go a long way to help but more support is needed. One of the regional cancer support networks has gone further to criticize the fact that so much is doled out in patient accommodation instead of advanced cancer treatment and care services.
A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.
ACT Biotech, a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly-potent nature of the antiangiogenic agent.
454 Life Sciences, a Roche Company, and NuGEN Technologies, announced today the development of a unique sample preparation method and high-throughput sequencing solution for small and degraded RNA samples.
Smart Use Solutions, the leading provider of inventory management software to the healthcare sector today announced it has been awarded Primary Supplier status for the provision of NHS inventory management solutions.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 12.7 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.69 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 55.56 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 10.67 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 15.79 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 88.16 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 26.47 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 0 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 37.64 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 21.21 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.9 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 0 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 95.45 | 82.93 |
News Archive
The Federal Government has announced a $560 million for new or upgraded cancer centres across Australia this week. The Cancer Council of Australia while welcoming this gesture has said that this is not the complete solution when it comes to helping regional and rural patients of Australia. This statement was made by the CEO Ian Olver who said that this "unprecedented" amount of money can go a long way to help but more support is needed. One of the regional cancer support networks has gone further to criticize the fact that so much is doled out in patient accommodation instead of advanced cancer treatment and care services.
A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.
ACT Biotech, a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly-potent nature of the antiangiogenic agent.
454 Life Sciences, a Roche Company, and NuGEN Technologies, announced today the development of a unique sample preparation method and high-throughput sequencing solution for small and degraded RNA samples.
Smart Use Solutions, the leading provider of inventory management software to the healthcare sector today announced it has been awarded Primary Supplier status for the provision of NHS inventory management solutions.
› Verified 6 days ago
Somerset Rehabilitation & Living Center Location: 43 Owens St, Bingham, Maine 04920 Phone: (207) 672-4041 |